Chemo‐immunotherapy for Older Patients with Chronic Lymphocytic Leukemia – Passé Yet?
Open Access
- 1 August 2019
- journal article
- editorial
- Published by Wiley in HemaSphere
- Vol. 3 (4), e275
- https://doi.org/10.1097/hs9.0000000000000275
Abstract
No abstract availableThis publication has 9 references indexed in Scilit:
- Ibrutinib Regimens versus Chemoimmunotherapy in Older Patients with Untreated CLLThe New England Journal of Medicine, 2018
- Ibrutinib blocks Btk-dependent NF-ĸB and NFAT responses in human macrophages during Aspergillus fumigatus phagocytosisBlood, 2018
- Ventricular Arrhythmias Following Ibrutinib Initiation for Lymphoid MalignanciesJournal of Invasive Cardiology, 2018
- Comorbidities predict inferior outcomes in chronic lymphocytic leukemia treated with ibrutinibCancer, 2018
- Characterization of atrial fibrillation adverse events reported in ibrutinib randomized controlled registration trialsHaematologica, 2017
- Ventricular arrhythmias and sudden death in patients taking ibrutinibBlood, 2017
- Economic Burden of Chronic Lymphocytic Leukemia in the Era of Oral Targeted Therapies in the United StatesJournal of Clinical Oncology, 2017
- Ibrutinib as Initial Therapy for Patients with Chronic Lymphocytic LeukemiaThe New England Journal of Medicine, 2015
- B-cell receptor signaling in chronic lymphocytic leukemiaBlood, 2011